Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: a propensity score-matched study
In conclusion, the overall efficacy and safety profile were similar between PD-L1 inhibitors and PD-1 inhibitors for the first-line treatment of ES-SCLC.
Authors
- Hui Zhu (ORCID: https://orcid.org/0000-0001-9422-3886)
- Shuangqing Lu
- Yingfan Guo
- Qinhao Xu
- Zhuoran Sun (ORCID: https://orcid.org/0000-0001-9509-6399)
- Yaru Tian (ORCID: https://orcid.org/0009-0000-5962-6890)
- Jiling Niu
Institutions
- Academy of Medical Sciences (GB)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1080/14796694.2025.2562731
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00